Verition Fund Management
CLDX icon

Verition Fund Management’s Celldex Therapeutics CLDX Stock Holding History

Verition Fund Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55,140
Closed -$1.43M – 3566
2025
Q3 		$1.43M Buy
55,140
+21,269
+63% +$493K 0.01% 2257
2025
Q2 		$689K Buy
33,871
+15,475
+84% +$301K ﹤0.01% 2734
2025
Q1 		$334K Buy
+18,396
New +$411K ﹤0.01% 2812
2022
Q2 		– Sell
-87,230
Closed -$2.97M – 2435
2022
Q1 		$2.97M Buy
87,230
+33,368
+62% +$1.07M 0.04% 697
2021
Q4 		$2.08M Buy
+53,862
New +$2.35M 0.02% 859
2021
Q2 		– Sell
-133,064
Closed -$2.74M – 1912
2021
Q1 		$2.74M Sell
133,064
-42,475
-24% -$975K 0.03% 339
2020
Q4 		$3.08M Buy
175,539
+7,915
+5% +$142K 0.03% 286
2020
Q3 		$2.49M Buy
+167,624
New +$1.96M 0.05% 212

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return